An arterial occlusion with clot leads to ischemia. In ischemic stroke this mechanism causes damage to the brain and hence neurological deficit according to the involved area. The window to treat this occlusion and to prevent damage is short is up to 6-8 hours. Successful recanalization depends on the tools that the operator can use that allow reopening of the vessel and that will reduce the damage to tissue. There is an advantage for tools that avoid using strong blood thinners or thrombolysis that can lead to secondary hemorrhage in the brain and a larger damage. Due to the fact that not all clots require or respond to the same treatment, the need for a variety of thrombectomy methods is fueled.
The potential market
Stroke is the third leading cause of death and the major cause of disability in adults. In the USA, each year ~795,000 people experience stroke. According to the January 2009 report by Millennium Research Group (MRG) entitled “U.S. Markets for Plaque and Thrombus Management Devices 2009,” the thrombectomy device market is expected to grow to more than $875 million by 2013. This includes sales of both aspiration and mechanical devices.
Development Stage and Development Status-Summary
The electric signals administered through the electrodes were found to attach to the clot firmly, enabling the surgeon to pull the clot from the artery (much like the other mechanical methods of thrombectomy). The technology was applied successfully In vitro and In vivo (swine, canine and rabbit). The animal experiments established feasibility and a great potential for the development of a clot retrieval catheter based on this technology. The treatment is based on low power electricity, it could be activated by a battery power supply, and In vivo safety tests related to the electrical risks, indicated a positive potential to achieve the required human safety.
Goals and Benefits
Currently, there isn’t any retrieval device that can be applied in distal, small vessels. The present technology will enable to enlarge the occasions and the efficacy of the clot retrieval procedures, especially for small brain vessels.
Potential Commercial Uses
Occlusions removal in Acute stroke, Myocardial infarction, PAD-Peripheral Arterial Disease, Deep venous thrombosis, and Pulmonary emboli.
Patent status
Priority date: 03.11.2008, current status: Patent pending in US, Europe, Israel
Contact for Licensing Information
Dr. Yael Rozen, BGN Technologies, E-mail: ulrozen@gmail.com
1586128335.jpg)